This bio-tech equity has grabbed my attention over the summer....most notably because of their Trospium drug. With approval of their closest competitor's (Eli Lilly) drug in the overactive bladder (OAB) being delayed earlier this month (requesting more date on metabolism and drug-to-drug interaction), it might seem that things might be getting brighter for IDEV. It appears that Trospium also avoids the shortcomings of Lilly's drug. Trospium has already been approved in Europe, and an NDA has already been filed and wiaccepted for a 12-month review.
Wachovia cut Indevus to "market perform" from "outperform" on September 12, 2003.
Do I see an opportunity? Is anyone else following this stock? |
